EVO
Evotec SE
EVO trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over EVO overall, supported by stronger fundamentals and lower modeled downside.
EVO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Under pressure |
EVO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EVO PE Valuation
EVO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect EVO's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over EVO on the outlook, with more favorable revenue expectations.
EVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.62 | -$0.14 |
| Q1 2026 | -$0.61 | +$0.03 |
| Q4 2025 | -$0.32 | +$0.29 |
| Q3 2025 | -$0.49 | +$0.05 |
| Q2 2025 | -$0.48 | +$0.06 |
| Q1 2025 | -$0.64 | -$0.35 |
| Q4 2024 | -$0.61 | -$0.35 |
| Q3 2024 | -$0.54 | -$0.24 |
EVO lost $0.62 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over EVO on earnings quality, reporting a profit while its opponent remains loss making.
EVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $162M | -15% |
| Q1 2026 | $176.9M | -20% |
| Q4 2025 | $278.7M | +13% |
| Q3 2025 | $182.1M | -11% |
| Q2 2025 | $190.2M | -6% |
| Q1 2025 | $222.2M | -4.2% |
| Q4 2024 | $245.8M | +9.9% |
| Q3 2024 | $205.4M | -5.8% |
EVO's revenue is shrinking: $162M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -19 points |
| Q1 2026 | -35% | -25 points |
| Q4 2025 | 9.6% | +6.5 points |
| Q3 2025 | -27% | -13 points |
| Q2 2025 | -16% | +41 points |
| Q1 2025 | -10% | -1.3 points |
| Q4 2024 | 3.1% | +8.8 points |
| Q3 2024 | -14% | -8.1 points |
EVO's operating margin was −36% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over EVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EVO on profitability, with a higher operating margin.
EVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$132.8M | -4534% |
| Q1 2026 | -$7.1M | +$52.5M |
| Q4 2025 | $51.7M | -5.2% |
| Q3 2025 | -$98.8M | -724% |
| Q2 2025 | $3M | +$112.7M |
| Q1 2025 | -$59.6M | +$45.8M |
| Q4 2024 | $54.6M | +$102.8M |
| Q3 2024 | $15.8M | +$43.8M |
EVO's free cash flow was −$187M over the past year, against $14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +403K shares |
| 1 year | +0.1% | +334K shares |
| 3 years | +0.5% | +1.7M shares |
| 5 years | +8.2% | +26.9M shares |
| Available history | +19% | +56M shares |
EVO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $171,079 |
EVO hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 3.4x | Elevated |
| Q2 2024 | 89.3x | High |
| Q1 2024 | 36.0x | High |
| Q4 2023 | 8.8x | High |
| Q3 2023 | 2.6x | Moderate |
| Q2 2023 | 156.6x | High |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -0.9x | Net Cash |
EVO's net debt is about 3.4 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 34.1 | Neutral |
EVO's weekly RSI is 38 (neutral) and its Stochastic is 34 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EVO PE vs Healthcare Sector
| Metric | EVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EVO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 6.4% above |
| 20 week MA | $1.85 | 10% below |
| 50 week MA | $2.57 | 35% below |
| 100 week MA | $3.25 | 49% below |
| 200 week MA | $5.60 | 70% below |
EVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 70% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EVO on trend strength, trading above more of its moving averages.
EVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.9 | $17.4 | +35% |
| 2021 | $17.4 | $22.6 | +30% |
| 2022 | $22.6 | $8.06 | -64% |
| 2023 | $8.06 | $11.7 | +46% |
| 2024 | $11.7 | $4.54 | -61% |
| 2025 | $4.54 | $3.11 | -31% |
| 2026 YTD | $3.11 | $1.66 | -47% |
EVO has finished lower in three of the last six years. It's down 47% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EVO on returns for 2026, with the stronger performance.